Item 1. Security and Issuer.
This joint statement on Schedule 13D is filed with respect to the common stock, par value $0.0001 per share (“Common Stock”), of Tourmaline Bio, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 93 Worcester St., Wellesley, MA 02481.
Item 2. Identity and Background.
(a) This Amendment No. 1 (this “Amendment”) amends and supplements the Schedule 13D originally filed with the Commission on May 21, 2021 (collectively, the “Original Schedule 13D”). This Amendment is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by, among other things, the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D and not in connection with a disposition of any shares by the Reporting Persons. Such dilution resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.
Sandip Agarwala, a Reporting Person on the Original Schedule 13D, is no longer a member of LCPIII, and accordingly, is no longer a Reporting Person.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Original Schedule 13D is hereby amended to add the following language:
(a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.
(e) On October 19, 2023, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock.
All Common Stock share amounts and percentage interests in this Amendment give effect to the Reverse Stock Split.